HUMA Latest News, Press Relases and Analysis

All

Press Releases

22 hours ago - By: Zacks Investment Research

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors

a day ago - By: Humacyte, Inc

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

14 days ago - By: Zacks Investment Research

Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing

21 days ago - By: Zacks Investment Research

Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why

24 days ago - By: ACCESS Newswire

D. Boral Capital Acted as Exclusive Placement Agent to Humacyte (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering

3 months ago - By: Benzinga

An Overview of Humacyte's Earnings

3 months ago - By: Zacks Investment Research

Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

a month ago - By: Benzinga - Mentions: SNWV CLRB APVO SPRB ...

12 Health Care Stocks Moving In Tuesday's Intraday Session

a month ago - By: Humacyte, Inc

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

a month ago - By: Zacks Investment Research

Humacyte, Inc. (HUMA) Outperforms Broader Market: What You Need to Know

2 months ago - By: Humacyte, Inc

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

2 months ago - By: Humacyte, Inc

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

3 months ago - By: Zacks Investment Research

Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?

3 months ago - By: Zacks Investment Research - Mentions: EDIT

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

3 months ago - By: The Motley Fool

Humacyte Posts Q2 Revenue Miss

3 months ago - By: Humacyte, Inc

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

3 months ago - By: Zacks Investment Research

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

4 months ago - By: Zacks Investment Research - Mentions: SBUX ORCL ITW ICE ...

Beat the Market the Zacks Way: Humacyte, Starbucks, Oracle in Focus

5 months ago - By: Humacyte, Inc

Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

5 months ago - By: Humacyte, Inc

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

5 months ago - By: Zacks Investment Research

Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?

6 months ago - By: Humacyte, Inc

HUMACYTE INC (HUMA) Stock News

HUMA Latest News, Press Relases and Analysis

Humacyte, Inc. (HUMA) Declines More Than Market: Some Information for Investors

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing

Humacyte, Inc. (HUMA) Laps the Stock Market: Here's Why

D. Boral Capital Acted as Exclusive Placement Agent to Humacyte (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering

An Overview of Humacyte's Earnings

Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

12 Health Care Stocks Moving In Tuesday's Intraday Session

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Humacyte, Inc. (HUMA) Outperforms Broader Market: What You Need to Know

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

Humacyte Posts Q2 Revenue Miss

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

Beat the Market the Zacks Way: Humacyte, Starbucks, Oracle in Focus

Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3

Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq